Objective. To evaluate the efficacy and safety of therapy with pure diosmin at a daily dose of 600 mg in symptomatic patients with chronic venous disease (CVD), as well as to evaluate patients’ adherence to the prescribed regimen. Material and methods. A multicenter, prospective, observational study was conducted. It included patients with CVD without skin changes and ulceration who presented with venous symptoms. Patients were prescribed with diosmin at a dose of 600 mg once daily to alleviate venous symptoms and reduce edema. The changes in edema/swelling and overall discomfort from CVD symptoms were assessed with a numeric rating scale (NRS). Treatment satisfaction and therapy adherence were also evaluated. Results. Our study included 1929 (72.5%) women and 731 (27.5%) men, with a mean age of 45.6±10.7 years. The overall discomfort score, assessed with NRS, decreased from 5.9±1.81 points at the first visit to 3.1±1.49 at the second visit (day 30) and 1.3±1.30 at the third visit (day 60) (p<0.0001). By the third visit, venous symptoms were completely relieved in 801 of 2463 (32.5%) patients. Edema/swelling were present in 1854 (69.7%) patients at the first visit, 829 at the second visit and 240 at the third visit (p<0.001). At the final visit, 92.6% of patients rated their treatment as «good» or «excellent». Patient adherence to the prescribed regimen was rated as good or excellent. 12 adverse events (AE) were reported, 9 of them were gastrointestinal, and only 1 AE led to discontinuation of the drug. Conclusion. Diosmin at a daily dose of 600 mg reduces the severity and frequency of venous symptoms and swelling. AE associated with diosmin are rare and, in most cases, do not necessitate discontinuation of treatment. Patients demonstrate high levels of treatment satisfaction and adherence to the prescribed regimen.
Suchkov et al. (Thu,) studied this question.